Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients

o Objectives from the Phase 1b study successfully met
o On track with the Phase 2 part of the study: first patients enrolled
o Preliminary efficacy data expected in 2H 2019
o Clinical trial in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer

Strasbourg, France, December 20, 2018, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that the primary endpoint (safety and tolerability) was met in the Phase 1b part of a trial combining TG4001 and avelumab, a human anti-programmed death ligand (PD-L1) antibody, as a treatment for HPV-16+ recurrent or metastatic malignancies, such as oropharyngeal squamous cell carcinoma of the head and neck (SCCHN).

.../...